|
1
|
Lortet-Tieulent J, Ferlay J, Bray F and
Jemal A: International patterns and trends in endometrial cancer
incidence, 1978–2013. J Natl Cancer Inst. 110:354–361. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arend RC, Jones BA, Martinez A and
Goodfellow P: Endometrial cancer: Molecular markers and management
of advanced stage disease. Gynecol Oncol. 150:569–580. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raglan O, Kalliala I, Markozannes G,
Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E,
Martin-Hirsch P, Tsilidis KK and Kyrgiou M: Risk factors for
endometrial cancer: An umbrella review of the literature. Int J
Cancer. 145:1719–1730. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spurdle AB, Bowman MA, Shamsani J and Kirk
J: Endometrial cancer gene panels: Clinical diagnostic vs research
germline DNA testing. Mod Pathol. 30:1048–1068. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levine MD, Pearlman R, Hampel H, Cosgrove
C, Cohn D, Chassen A, Suarez A, Barrington DA, McElroy JP, Waggoner
S, et al: Up-front multigene panel testing for cancer
susceptibility in patients with newly diagnosed endometrial cancer:
A multicenter prospective study. JCO Precis Oncol. 5:1588–1602.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian W, Bi R, Ren Y, He H, Shi S, Shan B,
Yang W, Wang Q and Wang H: Screening for hereditary cancers in
patients with endometrial cancer reveals a high frequency of
germline mutations in cancer predisposition genes. Int J Cancer.
145:1290–1298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cadoo KA, Mandelker DL, Mukherjee S,
Stewart C, DeLair D, Ravichandran V, Srinivasan P, Hurley D, Kemel
Y, Arnold AG, et al: Understanding inherited risk in unselected
newly diagnosed patients with endometrial cancer. JCO Precis Oncol.
3:PO.18.00338. 2019.
|
|
9
|
Long B, Lilyquist J, Weaver A, Hu C,
Gnanaolivu R, Lee KY, Hart SN, Polley EC, Bakkum-Gamez JN, Couch FJ
and Dowdy SC: Cancer susceptibility gene mutations in type I and II
endometrial cancer. Gynecol Oncol. 152:20–25. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ring KL, Bruegl AS, Allen BA, Elkin EP,
Singh N, Hartman AR, Daniels MS and Broaddus RR: Germline
multi-gene hereditary cancer panel testing in an unselected
endometrial cancer cohort. Mod Pathol. 29:1381–1389. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Samadder NJ, Riegert-Johnson D, Boardman
L, Rhodes D, Wick M, Okuno S, Kunze KL, Golafshar M, Uson PLS Jr,
Mountjoy L, et al: Comparison of universal genetic testing vs
guideline-directed targeted testing for patients with hereditary
cancer syndrome. JAMA Oncol. 7:230–237. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johnatty SE, Pesaran T, Dolinsky J, Yussuf
A, LaDuca H, James PA, O'Mara TA and Spurdle AB: Case-case analysis
addressing ascertainment bias for multigene panel testing
implicates BRCA1 and PALB2 in endometrial cancer. Hum Mutat.
42:1265–1278. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Karpel HC, Chern JY, Smith JM, Smith AJ
and Pothuri B: Utility of germline multi-gene panel testing in
patients with endometrial cancer. Gynecol Oncol. 165:546–551. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Susswein LR, Marshall ML, Nusbaum R, Vogel
Postula KJ, Weissman SM, Yackowski L, Vaccari EM, Bissonnette J,
Booker JK, Cremona ML, et al: Pathogenic and likely pathogenic
variant prevalence among the first 10,000 patients referred for
next-generation cancer panel testing. Genet Med. 18:823–832. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heald B, Mokhtary S, Nielsen SM, Rojahn S,
Yang S, Michalski ST and Esplin ED: Unexpected actionable genetic
variants revealed by multigene panel testing of patients with
uterine cancer. Gynecol Oncol. 166:344–350. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Daniels MS and Lu KH: Genetic
predisposition in gynecologic cancers. Semin Oncol. 43:543–547.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Jonge MM, de Kroon CD, Jenner DJ,
Oosting J, de Hullu JA, Mourits MJE, Gómez Garcia EB, Ausems MGEM,
Margriet Collée J, van Engelen K, et al: Endometrial cancer risk in
women with germline BRCA1 or BRCA2 mutations: Multicenter cohort
study. J Natl Cancer Inst. 113:1203–1211. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mur P, Garcia-Mulero S, Del Valle J,
Magraner-Pardo L, Vidal A, Pineda M, Cinnirella G, Martin-Ramos E,
Pons T, López-Doriga A, et al: Role of POLE and POLD1 in familial
cancer. Genet Med. 22:2089–2100. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wieme G, Kral J, Rosseel T, Zemankova P,
Parton B, Vocka M, Van Heetvelde M, Kleiblova P, Blaumeiser B,
Soukupova J, et al: Prevalence of germline pathogenic variants in
cancer predisposing genes in Czech and Belgian pancreatic cancer
patients. Cancers (Basel). 13:44302021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lhotova K, Stolarova L, Zemankova P, Vocka
M, Janatova M, Borecka M, Cerna M, Jelinkova S, Kral J, Volkova Z,
et al: Multigene panel germline testing of 1333 Czech patients with
ovarian cancer. Cancers (Basel). 12:9562020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Soukupova J, Zemankova P, Lhotova K,
Janatova M, Borecka M, Stolarova L, Lhota F, Foretova L, Machackova
E, Stranecky V, et al: Validation of CZECANCA (CZEch CAncer paNel
for clinical application) for targeted NGS-based analysis of
hereditary cancer syndromes. PLoS One. 13:e01957612018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A MapReduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
1000 Genomes Project Consortium, .
Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker
RE, Kang HM, Marth GT and McVean GA: An integrated map of genetic
variation from 1,092 human genomes. Nature. 491:56–65. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karczewski KJ, Francioli LC, Tiao G,
Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A,
Birnbaum DP, et al: The mutational constraint spectrum quantified
from variation in 141,456 humans. Nature. 581:434–443. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Exome Variant Server NGESPE, ; Available
online:, . http://evs.gs.washington.edu/EVS/15–March. 2022
|
|
26
|
Landrum MJ, Lee JM, Riley GR, Jang W,
Rubinstein WS, Church DM and Maglott DR: ClinVar: Public archive of
relationships among sequence variation and human phenotype. Nucleic
Acids Res. 42:(Database Issue). D980–D985. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miller DT, Lee K, Chung WK, Gordon AS,
Herman GE, Klein TE, Stewart DR, Amendola LM, Adelman K, Bale SJ,
et al: ACMG SF v3.0 list for reporting of secondary findings in
clinical exome and genome sequencing: A policy statement of the
American college of medical genetics and genomics (ACMG). Genet
Med. 23:1381–1390. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang
J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, et al:
Pathogenic germline variants in 10,389 adult cancers. Cell.
173:355–370.e14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
LaDuca H, Polley EC, Yussuf A, Hoang L,
Gutierrez S, Hart SN, Yadav S, Hu C, Na J, Goldgar DE, et al: A
clinical guide to hereditary cancer panel testing: Evaluation of
gene-specific cancer associations and sensitivity of genetic
testing criteria in a cohort of 165,000 high-risk patients. Genet
Med. 22:407–415. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vietri MT, D'Elia G, Caliendo G,
Casamassimi A, Federico A, Passariello L, Cioffi M and Molinari AM:
Prevalence of mutations in BRCA and MMR genes in patients affected
with hereditary endometrial cancer. Med Oncol. 38:132021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stolarova L, Kleiblova P, Janatova M,
Soukupova J, Zemankova P, Macurek L and Kleibl Z: CHEK2 germline
variants in cancer predisposition: Stalemate rather than checkmate.
Cells. 9:26752020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yen TT, Wang TL, Fader AN, Shih IM and
Gaillard S: Molecular classification and emerging targeted therapy
in endometrial cancer. Int J Gynecol Pathol. 39:26–35. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
León-Castillo A, Britton H, McConechy MK,
McAlpine JN, Nout R, Kommoss S, Brucker SY, Carlson JW, Epstein E,
Rau TT, et al: Interpretation of somatic POLE mutations in
endometrial carcinoma. J Pathol. 250:323–335. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Green AK, Feinberg J and Makker V: A
review of immune checkpoint blockade therapy in endometrial cancer.
Am Soc Clin Oncol Educ Book. 40:1–7. 2020.PubMed/NCBI
|
|
35
|
Bychkovsky BL, Lo MT, Yussuf A, Horton C,
Richardson M, LaDuca H, Garber JE and Rana HQ: Prevalence and
spectrum of pathogenic variants among patients with multiple
primary cancers evaluated by clinical characteristics. Cancer.
128:1275–1283. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stolarova L, Jelinkova S, Storchova R,
Machackova E, Zemankova P, Vocka M, Kodet O, Kral J, Cerna M,
Volkova Z, et al: Identification of germline mutations in melanoma
patients with early onset, double primary tumors, or family cancer
history by NGS analysis of 217 genes. Biomedicines. 8:4042020.
View Article : Google Scholar : PubMed/NCBI
|
